Our Pipeline
Our current pipeline is focused on UDB412, a promising lead candidate for the treatment of the severe pain of Trigeminal Neuralgia, a debilitating facial pain condition with a significant unmet medical need. We intend to broaden the indication of UDB412 to other neuropathic pain conditions, such as diabetic neuropathic pain, chemo-induced peripheral neuropathy and post-herpetic neuralgia.
UDB412 for Trigeminal Neurlagia
Clinical Stage: pre-IND
UDB412 is a repurposed drug that we are reformulating into an Oral Thin Film for the treatment of pain in Trigeminal Neuralgia patients.
Trigeminal neuralgia, also known ‘tic douloureux’, is one of the most common forms of chronic neuropathic facial pain. It is characterized by sudden, brief, and excruciating facial pain attacks leading to a severe reduction in the quality of life of affected patients. Often termed the “suicide disease” it is considered one of the most severe forms of pain a person can experience.
Approximately 55,000 people have Trigeminal Neuralgia in the US, and there is a huge unmet need for safer and more effective therapies.
About UDB412
UDB412 was discontinued in the US for its original indication for marketing reasons, has an excellent safety record, and continues to be used for its original indication outside the US. Compared to the standard of Care (SOC) drugs, e.g. Carbamezapine it has fewer side effects and contraindications.
UDB412 is being developed via the FDA’s 505(b)(2) pathway as a reformulation of the original tablet form into an oral thin film (OTF). The OTF dissolves quickly on the tongue, without the need for water, and will enable patients to take their medication even during an attack of Trigeminal Neurlagia, greatly improving the management of their pain.